The diverse functions of the E3 ubiquitin ligases, by targeting both wtp53 and mtp53, not only achieve distinct cellular outcomes leading to cancer cell survival or death, but also open new opportunities for potential targeting therapy. The gene discussed is PRKN; the disease is cancer.